| Ref No | Member | Question | Tabled | Status |
|
AQW 47897/22-27
|
Mrs Linda Dillon
(SF - Mid Ulster)
|
To ask the Minister of Health, given the recent decision by NHS England and the National Institute for Health and Care Excellence to make mirvetuximab soravtansine available for patients with folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube and primary peritoneal cancers, to detail (i) whether this treatment will be made available to patients in the North; (ii) whether any assessment has been undertaken by his Department and the Health and Social Care Board in relation to the clinical and cost effectiveness of the treatment; (iii) the anticipated timescale for any decision on routine commissioning; and (iv) any steps that are being taken to ensure that women in the North not disadvantaged in accessing innovative cancer treatments available elsewhere in these islands.
[Priority Written]
| 04/06/2026 |
To be answered by 12/06/2026
|
|
AQW 47779/22-27
|
Mrs Linda Dillon
(SF - Mid Ulster)
|
To ask the Minister for Communities to detail any consideration he has given to awarding additional housing allocation points to young people leaving care, to support their transition to independent living.
| 03/06/2026 |
To be answered by 18/06/2026
|
|
AQW 47778/22-27
|
Mrs Linda Dillon
(SF - Mid Ulster)
|
To ask the Minister for Communities to detail any consideration he has given to awarding housing allocation points to foster families, whose housing circumstances impact their ability to provide foster placements.
| 03/06/2026 |
To be answered by 18/06/2026
|
|
AQW 47659/22-27
|
Mrs Linda Dillon
(SF - Mid Ulster)
|
To ask the Minister of Health, given reports of tyres being stored at the Moygashel bonfire site, (i) to detail any steps his Department is taking to raise awareness of the health risks associated with the burning of tyres and other toxic materials; and (ii) whether he has made representations to relevant authorities in relation to the protection of public health.
| 02/06/2026 |
To be answered by 17/06/2026
|
|
AQW 47658/22-27
|
Mrs Linda Dillon
(SF - Mid Ulster)
|
To ask the Minister of Health to detail any engagement his Department has had with the UK National Screening Committee in relation to its evaluation of newborn screening for metachromatic leukodystrophy.
| 02/06/2026 |
To be answered by 17/06/2026
|
|
AQW 47657/22-27
|
Mrs Linda Dillon
(SF - Mid Ulster)
|
To ask the Minister of Health to detail any actions he will take to ensure Health and Social Care Trusts implement the NI Public Services Ombudsman's May 2026 recommendations following findings of failures in the investigation and treatment of a patient's infection by the Northern Health and Social Care Trust.
| 02/06/2026 |
To be answered by 17/06/2026
|
|
AQW 47536/22-27
|
Mrs Linda Dillon
(SF - Mid Ulster)
|
To ask the Minister of Health whether (i) any assessment has been made of the potential impact of daraxonrasib, a KRAS-targeting therapy for advanced pancreatic cancer, on patient outcomes; and (ii) his Department is engaging with relevant regulatory bodies to ensure timely access to the treatment for eligible patients, should it receive regulatory approval.
| 01/06/2026 |
To be answered by 16/06/2026
|
|
AQW 47535/22-27
|
Mrs Linda Dillon
(SF - Mid Ulster)
|
To ask the Minister of Health to detail any guidance that is provided to Health and Social Care Trusts on recording the motivation or nature of abuse directed at staff, including whether incidents are classified as racial, sectarian, sexual, homophobic, transphobic or disability-related.
| 01/06/2026 |
To be answered by 16/06/2026
|
|
AQW 47534/22-27
|
Mrs Linda Dillon
(SF - Mid Ulster)
|
To ask the Minister of Health whether Health and Social Care Trusts record the protected characteristics of staff who are subjected to violence or abuse in the workplace, including sex, race, religion, ethnicity and disability.
| 01/06/2026 |
To be answered by 16/06/2026
|
|
AQW 47303/22-27
|
Mrs Linda Dillon
(SF - Mid Ulster)
|
To ask the Minister of Health in light of recommendations from the UK National Screening Committee that only a small number of high-risk men should receive routine prostate cancer screening, to detail (i) any steps he will take to improve prostate cancer screening, early diagnosis and awareness; and (ii) whether any consideration will be given to expanding access to prostate-specific antigen testing for men at higher risk of the disease, including those with a family history and Black men.
| 28/05/2026 |
To be answered by 12/06/2026
|
|